|
|
|
By AR Welch, Editorial & Community Director, Advancing RNA | As I read through the FDA's draft platform designation guidance and listened to various panel discussions the past few months, a handful of additional observations and considerations came to mind that are important to reiterate for the RNA space, particularly as we advance into therapeutics development. |
|
|
|
J. Stubenrauch & S. Deutsch, Nutcracker Therapeutics | Nutcracker's unique approach to scaling up to clinical manufacturing — which brings unique challenges compared to traditional biologics — relies on microfluidics. |
|
|
|
In this clip from a recent Advancing RNA LIVE event, panelists address a question about where the best opportunities exist upstream and/or downstream to increase mRNA manufacturing efficiencies. |
|
|
|
| The Heroes Of Vaccine Development: Lipid Nanoparticles | White Paper | By Michael Nguyen, Ph.D., Helix Biotech | Lipid nanoparticles (LNPs) have played a crucial role in COVID-19 vaccine development as efficient mRNA delivery systems, exhibiting versatility and effectiveness in accelerating the process. |
|
|
|
|
|
| Keys To Successful mRNA Manufacturing | Webinar | MilliporeSigma | How can PCR-based technology accelerate mRNA development and manufacturing and design principles/critical parameters to enable the rapid development of lipids for RNA formulation? |
|
|
.png){kind=logo}
